TSX-V: ELC

Investors

Media Coverage

On the US Vanadium web site:

May 27, 2025 Tyfast and US Vanadium Sign an MOU to Industrially Scale a New Class of Metal Oxide Anode to Power Batteries in Heavy Duty Vehicles
September 20, 2022 U.S. Vanadium’s New $5.8 Million Upgrade Improves Vanadium Recovery, Increases Recycling, and Supports Continued Production Rates for Ultra-High-Purity Electrolyte for Vanadium Redox Flow Batteries
February 24, 2022 U.S. Vanadium Expands Sales Agreement with CellCube for up to 3 Million Liters/Year of Ultra-High-Purity Vanadium Redox Flow Battery Electrolyte

On the BioAegis web site:

May 6, 2025 BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 17, 2024 October 17, 2024: BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
© 2025 Elysee Development Corp.
All rights reserved.